Febuxostat, Indian WHO-GMP supply for chronic hyperuricemia in gout
Febuxostat lowers serum uric acid by inhibiting xanthine oxidase, and it has done so reliably for gout patients since regulatory approval in the mid-2000s. What every procurement desk sourcing it also needs on file is the 2019 US FDA boxed warning for cardiovascular death, drawn from the CARES trial, and the parallel European caution against use in patients with existing ischaemic heart disease or heart failure. M Care supplies febuxostat tablets sourced from WHO-GMP certified Indian manufacturers to licensed importers, hospital pharmacies and tender desks across our served export markets, with that warning documented plainly rather than left for the buyer to discover downstream.
Febuxostat exporter and bulk supplier from India.
Procurement desks sourcing febuxostat in bulk are usually replacing or supplementing an allopurinol line for patients who cannot tolerate it, so the paperwork trail (CoA, batch-specific dissolution data, stability data for tropical climates) matters more than for a first-line drug. M Care packages febuxostat consignments from WHO-GMP certified Indian manufacturers with the documentation set tender desks and hospital pharmacy committees expect, and flags the cardiovascular warning language explicitly in the batch dossier rather than leaving procurement teams to find it themselves.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Xanthine oxidase inhibitor (non-purine selective), sourced and documented for export.
Xanthine oxidase inhibitor for chronic hyperuricemia in gout. Oral tablets, 40 mg and 80 mg film-coated strengths are the standard global presentations. Carries a US FDA boxed warning (cardiovascular death, added 2019 after the CARES trial) and an EU warning against use in ischaemic heart disease or congestive heart failure. Not a controlled substance; not scheduled. Guideline positioning in most markets is second-line, after an adequate trial of allopurinol, or first-line specifically when allopurinol is contraindicated or not tolerated. Contraindicated for concomitant use with azathioprine or mercaptopurine. Baseline and periodic liver function monitoring is standard practice. Sourced from WHO-GMP certified Indian manufacturers; M Care's own quality credential is ISO 9001:2015.
Active ingredient
Febuxostat. Xanthine oxidase inhibitor (non-purine selective).
Forms and strengths
40 mg; 80 mg.
Indications
Febuxostat is a non-purine selective inhibitor of xanthine oxidase used to lower serum uric acid in patients with chronic hyperuricemia associated with gout. It is not indicated for asymptomatic hyperuricemia and carries cardiovascular safety warnings in several major markets.
Administration
Oral. Film-coated tablets.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Licensed pharmaceutical importers, hospital and tender pharmacy procurement desks, and wholesale distributors across the Gulf, Africa, UK/EU and Southeast Asian markets M Care serves. Buyers typically fall into two groups: rheumatology and internal medicine formularies replacing or supplementing allopurinol for patients who cannot tolerate it, and tender desks stocking febuxostat as a listed second-line gout therapy per national treatment guidelines. M Care does not supply into India, as India is excluded as a destination market for our export operations.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on febuxostat.
Febuxostat's clinical case rests on two facts that pull in different directions and both need stating plainly. First, it is genuinely useful where allopurinol fails: it does not require the renal dose titration that complicates allopurinol use in patients with reduced kidney function, and it works for patients with allopurinol hypersensitivity, a real and sometimes severe reaction. Second, the CARES trial (the FDA-mandated post-marketing cardiovascular outcomes study that led to the 2019 boxed warning) found more cardiovascular deaths and more all-cause mortality in the febuxostat arm than the allopurinol arm, specifically in gout patients who already had cardiovascular disease at enrollment. That is the population where the warning bites hardest; it is not a signal that has been shown to apply to febuxostat-naive patients without cardiac history to anything like the same degree, but regulators have chosen to warn broadly rather than narrowly, and the honest response for an exporter is to pass that caution along rather than soften it. Baseline and periodic LFTs are standard practice given reported hepatic enzyme elevations. The azathioprine and mercaptopurine contraindication is absolute and mechanistic, not a relative caution, because febuxostat inhibiting xanthine oxidase directly blocks the pathway that clears those drugs. None of this makes febuxostat unsuitable for export; it makes accurate labeling and dossier-level warning language non-negotiable, and it is why treatment guidelines across our served markets keep it in a second-line role behind allopurinol rather than promoting it as a general first choice.
The documentation pack a regulator actually asks for.
Sourced exclusively from WHO-GMP certified Indian manufacturing facilities. M Care Exports' own quality management system is ISO 9001:2015 certified; M Care is a merchant-exporter and does not itself hold WHO-GMP or WHO-PQ status, as those are manufacturing-site certifications. Every febuxostat consignment ships with manufacturer CoA and batch documentation, and the applicable cardiovascular warning language is included in the dossier pack provided to the buyer. Buyers are responsible for confirming febuxostat's registration status and any local labeling requirements with their own national regulatory authority before import; M Care does not act as a registered agent or MAH in destination markets unless separately contracted to do so.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
US FDA boxed warning (added February 2019, based on the CARES post-marketing safety trial) for increased risk of cardiovascular death and all-cause mortality versus allopurinol in gout patients with pre-existing cardiovascular disease.
EU/UK labeling carries a related caution against use in patients with ischaemic heart disease or congestive heart failure.
Hard contraindication with concomitant azathioprine or mercaptopurine.
Not a scheduled or controlled substance in any served market and not withdrawn anywhere; remains approved and marketed in the US, EU, UK, and across Gulf and African regulatory frameworks referencing these approvals.
Marketing claims are narrowed accordingly: no safety superiority claims over allopurinol, no claims for use in patients with known cardiac disease, and no positioning as first-line therapy.
Adjacent lines procurement desks order alongside febuxostat.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for febuxostat.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Febuxostat supply, the specific questions.
Why does febuxostat carry a cardiovascular warning, and does that rule it out for export?
The US FDA added a boxed warning in February 2019 after the CARES post-marketing trial found a higher rate of cardiovascular death and all-cause mortality with febuxostat compared to allopurinol in gout patients who already had cardiovascular disease. The European label carries a related caution against use in patients with ischaemic heart disease or congestive heart failure. This does not remove febuxostat from legitimate trade; it remains an approved, widely prescribed molecule in the US, EU, UK, Gulf and many other markets. It does mean the warning language belongs in every dossier and marketing conversation, and that febuxostat should not be positioned as a general-purpose gout drug for patients with known cardiac disease.
Is febuxostat first-line or second-line therapy for gout?
In most national guidelines (ACR, EULAR-aligned protocols used across our export markets) allopurinol is the recommended first-line urate-lowering therapy. Febuxostat is generally positioned second-line, for patients who cannot tolerate allopurinol, do not reach target serum urate on it, or have a contraindication such as allopurinol hypersensitivity. Buyers should size procurement volumes against that second-line role rather than assuming first-line demand.
What monitoring does febuxostat require that a buyer's clinical staff should know about?
Baseline liver function tests are recommended before starting therapy, with periodic monitoring thereafter, since hepatic enzyme elevations have been reported. Serum uric acid is checked to confirm the drug is reaching target levels (below 6 mg/dL in most treat-to-target protocols). During the first months of treatment, gout flares can transiently increase as uric acid drops and crystals mobilize; prescribers commonly co-prescribe a low-dose NSAID or colchicine for prophylaxis rather than stopping febuxostat.
Can febuxostat be combined with azathioprine or mercaptopurine?
No. This is a hard contraindication in every major label. Febuxostat inhibits xanthine oxidase, the same enzyme that metabolizes azathioprine and 6-mercaptopurine, and co-administration can cause dangerous accumulation of these agents leading to bone marrow suppression. Hospital pharmacy teams sourcing febuxostat for transplant or rheumatology units in particular should have this flagged in dispensing protocols.
Does febuxostat need renal dose adjustment?
Current major labels do not require a dose reduction for mild to moderate renal impairment, which is one of febuxostat's practical advantages over allopurinol in patients with reduced kidney function, since allopurinol dosing in renal impairment is more complex. Data in severe renal impairment is more limited and prescribing information should be reviewed by the treating clinician for that population; M Care does not provide dosing guidance and defers entirely to the product's approved label and the prescriber.
Which strengths and pack formats does M Care source?
Standard global presentations are 40 mg and 80 mg film-coated tablets, matching typical starting and titration doses used in most markets. Buyers should confirm exact pack sizes, blister configuration and shelf-life against their tender specification at enquiry stage; M Care does not publish standing stock volumes or lead times and confirms these per order against manufacturer availability.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.